(Q37087865)

English

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

scientific article published on 31 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). (English)

1 reference

Europe PubMed Central

18 August 2017

diabetic nephropathy

1 reference

based on heuristic

inferred from title

author name string

Linda F Fried

1

1 reference

Europe PubMed Central

18 August 2017

William Duckworth

2

1 reference

Europe PubMed Central

18 August 2017

Jane Hongyuan Zhang

3

1 reference

Europe PubMed Central

18 August 2017

Theresa O'Connor

4

1 reference

Europe PubMed Central

18 August 2017

Mary Brophy

5

1 reference

Europe PubMed Central

18 August 2017

Nicholas Emanuele

6

1 reference

Europe PubMed Central

18 August 2017

Grant D Huang

7

1 reference

Europe PubMed Central

18 August 2017

Peter A McCullough

8

1 reference

Europe PubMed Central

18 August 2017

Paul M Palevsky

9

1 reference

Europe PubMed Central

18 August 2017

Stephen Seliger

10

1 reference

Europe PubMed Central

18 August 2017

Stuart R Warren

11

1 reference

Europe PubMed Central

18 August 2017

Peter Peduzzi

12

1 reference

Europe PubMed Central

18 August 2017

VA NEPHRON-D Investigators

13

1 reference

Europe PubMed Central

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

31 December 2008

1 reference

Europe PubMed Central

18 August 2017

Clinical Journal of the American Society of Nephrology

1 reference

Europe PubMed Central

18 August 2017

4

1 reference

Europe PubMed Central

18 August 2017

2

1 reference

Europe PubMed Central

18 August 2017

361-368

1 reference

Europe PubMed Central

18 August 2017

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Surrogate end points for clinical trials of kidney disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

The ethics of placebo-controlled trials--a middle ground

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

29 September 2017

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

27 June 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

Add-on angiotensin receptor blockade with maximized ACE inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2637584

3 September 2018

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controversy about COOPERATE ABPM trial data

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The COOPERATE trial: a letter of concern

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic kidney disease and cardiovascular disease in the Medicare population

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19118120

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2215/CJN.03350708

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37087865&oldid=1757002587"